On August 26, the U.S. Food and Drug Administration (FDA) granted approval to Revolution Medicines for its oral therapy Rasonque (generic name: daraxonrasib), designated for adults with metastatic pancreatic adenocarcinoma who have undergone at least one prior systemic treatment or are unsuitable for multi-agent combination regimens. This marks the inaugural broad-spectrum RAS inhibitor authorized for this specific indication. The company confirmed the drug is now available for prescription across the United States, with a recommended once-daily oral dose of 300 milligrams to be continued until disease progression or unacceptable toxicity emerges. The wholesale acquisition cost stands at $39,800 per 30-day supply.

The approved labeling covers patients both with and without identifiable tumor RAS mutations, notably eliminating any requirement for companion diagnostic testing. According to the National Cancer Institute, approximately 67,000 new pancreatic cancer cases arise annually in the U.S., with pancreatic adenocarcinoma representing 90% to 95% of these diagnoses. The American Cancer Society estimates around 52,000 deaths per year from this disease, with a five-year overall survival rate of approximately 13%. Since pancreatic cancer frequently remains undetected until metastasis, prior second-line options have largely relied on cytotoxic chemotherapy. More than 90% of pancreatic cancer cases are driven by RAS pathway alterations, with mutations such as G12D, G12V, and G12R historically lacking accessible targeted therapies. Rasonque functions as a RAS(ON) multi-selective, non-covalent tri-complex inhibitor, working with cyclophilin A to block the binding of multiple wild-type and mutant RAS proteins to downstream effector molecules.

Accelerated Regulatory Pathway

Angelo de Claro, director of the FDA's Oncology Center of Excellence, highlighted that the therapy delivered unprecedented results in an area of substantial unmet medical need, with approval arriving approximately 6.5 months ahead of the Prescription Drug User Fee Act target date. Acting Commissioner Kyle Diamantas characterized the approval as providing a critical new option for a historically challenging cancer. The application received breakthrough therapy designation, orphan drug designation, and priority review status, while also being included in the Commissioner's National Priority Review Voucher pilot program. Under the Project Orbis framework, the FDA conducted parallel review with Health Canada, with the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency participating as official observers.

Key Phase III Efficacy Data

The approval rests on findings from the global, randomized, open-label, multicenter Phase III trial RASolute 302 (NCT06625320). This study enrolled 500 patients with metastatic pancreatic adenocarcinoma who had progressed following one prior systemic therapy, randomizing them 1:1 to either daily oral daraxonrasib at 300 milligrams or investigator-selected standard cytotoxic chemotherapy from four options. The primary endpoints focused on progression-free survival and overall survival in the RAS G12-mutated population, with secondary endpoints encompassing the same measures across the full study cohort alongside objective response rate, duration of response, and patient-reported quality of life. Trial sites spanned North America, Europe, and Asia, with Brian Wolpin, director of the Hale Pancreatic Cancer Research Center at Dana-Farber Cancer Institute and Harvard Medical School professor, serving as principal investigator.

Results presented at the 2026 American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine demonstrated substantial benefit. In the intention-to-treat population, median overall survival reached 13.2 months (95% CI 10.0 to not estimable) in the investigational arm versus 6.7 months (5.8 to 8.0) with chemotherapy, yielding a hazard ratio of 0.40 (0.30 to 0.53) and a 60% reduction in mortality risk. Median progression-free survival measured 7.2 months (5.7 to 7.5) compared to 3.6 months (2.9 to 4.2), with a hazard ratio of 0.49 (0.38 to 0.64). Objective response rates reached 30% (25% to 36%) versus 11% (7% to 15%). The company noted consistent directional results in the RAS G12-mutated subgroup. Analysis from Dana-Farber indicated that among patients with known RAS G12 mutations, 33.2% in the investigational arm achieved significant tumor shrinkage or disappearance versus 11.8% with chemotherapy, while overall population response rates were 31.6% versus 11.2%. The FDA label reflects the full-population figures of 30% versus 11%.

Wolpin emphasized that directly inhibiting RAS can produce meaningful differences for metastatic pancreatic cancer patients, positioning this drug as a potential new standard of care for adults who have completed at least one prior systemic line or are unsuitable for multi-agent regimens. Julie Gralow, chief medical officer of ASCO, described the data as a "grand slam" during the annual meeting discussion. Rachna Shroff from the University of Arizona Cancer Center noted the trial addressed clinically important and meaningful endpoints, while Andrew Coveler of Fred Hutchinson Cancer Center characterized this as one of the most anticipated approvals he could recall, acknowledging the drug offers significant improvement rather than a cure.

Safety Profile

The prescribing information includes warnings for cutaneous and soft tissue toxicity, stomatitis and oral cavity disorders, diarrhea, gastrointestinal perforation, interstitial lung disease/pneumonitis, and embryo-fetal toxicity. The FDA announcement listed common adverse reactions including rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and bleeding. Trial analysis revealed treatment-related rash in 85.5% of investigational arm patients, with grade 3 or higher severity in 13.7%. Stomatitis represented the most frequent grade 3 or higher treatment-related adverse event at 12%. Discontinuation due to adverse events occurred in 1.2% of the investigational group versus 11.2% in the chemotherapy arm. The company reported no new safety signals in Phase III relative to earlier Phase I/II findings.

Commercial Availability and Future Development

Revolution Medicines confirmed in its 8-K filing that the wholesale acquisition cost for Rasonque in the U.S. is $39,800 per 30-day supply at the recommended daily dose, with tablets available for physician prescribing immediately. The company simultaneously launched a patient support program called (ON)Path to assist with insurance navigation, financial assistance, and medication education. Packaging consists of 150-milligram tablets consistent with the recommended once-daily 300-milligram dose. Chief Executive Officer and Chairman Mark Goldsmith stated that the global Phase III results position this drug as a potential new standard of care for metastatic pancreatic cancer, with ongoing regulatory discussions aimed at expanding access internationally. Anna Berkenblit, chief scientific and medical officer of the Pancreatic Cancer Action Network, noted that the oral tablet presents a lower treatment burden compared to standard intravenous chemotherapy.

The approved label specifically covers second-line treatment and patients unsuitable for multi-agent combination therapy in metastatic pancreatic adenocarcinoma. First-line indications, locally advanced disease, and other tumor types fall outside this approval scope. The company indicated the same molecule is advancing in global Phase III registration programs for pancreatic cancer and RAS-mutated metastatic non-small cell lung cancer, having already secured breakthrough therapy designation for non-G12C KRAS mutations in locally advanced or metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and anti-PD-(L)1 antibodies. Another RAS inhibitor in the pipeline, zoldonrasib, entered Phase III in June for first-line RAS G12D metastatic pancreatic cancer in combination with chemotherapy.

Outside the United States, daraxonrasib remains an investigational agent. The European Medicines Agency's Committee for Medicinal Products for Human Use has initiated rolling review with orphan drug designation for pancreatic cancer and high priority under the Cancer Medicines Pathway initiative. Health Canada continues parallel review under Project Orbis without synchronized results to date. Following the release of Phase III topline data in April, regulators opened expanded access for certain patients in May, with this approval converting investigational access to formal prescription status. Questions regarding first-line entry, European and Japanese approval timelines, and coverage decisions by commercial insurers and public payers for the $39,800 monthly cost remain unresolved as of the August 26 approval announcement.